All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View lym content recommended for you

EHA2022 abstracts: What's hot in lymphoma and CLL?

By Megan Lee,Ellen Jenner,Ella Dixon

Jun 6, 2022

To help navigate the exciting content being presented at the EHA2022 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

Indolent and mantle cell NHL

S205	Zanubrutinib + obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
S206	Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the GALLIUM study
S208	Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma: primary analysis of the global phase 2 study TIDAL
S209	Primary results from the phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle-cell lymphoma

Hodgkin lymphoma

S200	Improved overall survival with first-line brentuximab vedotin plus chemotherapy in patients with stage III/IV classical Hodgkin lymphoma: 6-year analysis of ECHELON-1
S201	Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
S203	Abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma: pre-planned interim analysis of the international GHSG phase II AERN trial
S204	Pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma with slow early response to frontline chemotherapy: The phase 2, open-label, KEYNOTE-667 study

T-cell lymphoma

S218

A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma

Aggressive B-NHL

LB2364	Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a phase 2 study
LB2370	R-CODOX-M/R-IVAC versus dose-adjusted(DA)-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma; first results of a multi-center randomized HOVON/SAKK trial
P1190	Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma from the POLARIX trial
S211	Clinical and patient-reported outcomes in a phase 3 study of axicabtagene ciloleucel (axi-cel) vs standard-of-care in elderly patients with relapsed/refractory large b-cell lymphoma (ZUMA-7)
S212	Phase I study of YTB323, a chimeric antigen receptor (CAR)-T cell therapy manufactured using T-Charge™, in patients with relapsed/refractory diffuse large B-cell lymphoma
S220	Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: pivotal phase II expansion results
S258	Lisocabtagene maraleucel (liso-cel) as second-line therapy for R/R large B-cell lymphoma (LBCL) in patients not intended for HSCT: primary analysis from the phase 2 PILOT study

Chronic lymphocytic leukemia (CLL)

LB2365	Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial
S145	The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial
S147	Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study
S148	Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study

Advances in disease biology

P1284	Liquid biopsy by ultra-deep sequencing plus PET-CT monitoring in real-life follicular lymphoma patients
S101	Genetic and epigenetic factors driving primary mediastinal B-cell lymphoma pathogenesis and outcome
S143	Transcriptomic characterization of MRD response and non-response in patients treated with fixed-duration venetoclax-obinutuzumab
S225	Circulating tumor DNA is a prognostic biomarker at baseline and improves the accuracy of interim PET in classic Hodgkin lymphoma

EHA2022 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022

Your opinion matters

Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?

Subscribe to get the best content delivered to your inbox